Naltrexone

BreastfeedingPediatric
  • TRADE NAMES: Antaxone; Celupan; Contrave (Takeda); Depade (Mallinckrodt); Nalorex (Bristol-Myers Squibb); Nemexin; Opizone (Genus); ReVia (Meda); Trexan; Troxyca (Pfizer); Vivitrex (Alkermes); Vivitrol (Alkermes)
  • INDICATIONS: Substance abuse, opioid dependence, alcohol dependence
  • CLASS: Opioid antagonist
  • HALF-LIFE: 4 hours
CLINICALLY IMPORTANT, POTENTIALLY HAZARDOUS INTERACTIONS WITH:

Lofexidine, Opioid analgesics, Opioid containing medications

PREGNANCY CATEGORY: C

Naltrexone has the capacity to cause hepatocellular injury when given in excessive doses.

Troxyca is naltrexone and oxycodone.

Contra-indicated in acute hepatitis or liver failure; patients receiving opioid analgesics, with current physiologic opioid dependence, or in acute opioid withdrawal.

Our database has 54 adverse reactions for this drug across the following areas

Please login to see the rest of this drug profile


Not a subscriber? Click here to subscribe

SKIN
HAIR
MUCOSAL
CARDIOVASCULAR
CENTRAL NERVOUS SYSTEM
NEUROMUSCULAR/SKELETAL
GASTROINTESTINAL/HEPATIC
RESPIRATORY
OCULAR
LOCAL
OTHER


Visit Informa

Click on the DRUG REVIEW ARTICLE tab (above) to see a review of naltrexone/bupropion in the Taylor & Francis journal Expert Opinion on Drug Safety. (Note that non-subscribers to the journal will only be able to see an abstract of the article.)

Page last updated 09/19/2018

Drug Eruption Mobile Site

Symbol key

Incidence info

  • <1%
  • 1-5%
  • 5-10%
  • 10-15%
  • 15-20%
  • 20-30%
  • >30%

Seriousness info

  • Hospitalization possible
  • Life threatening
  • Fatal

Warnings in other populations info

  • Breast feeding
  • Geriatric
  • Pediatric